biotech
FDA Approves Genezyme's Myozyme
Filed in archive Drugs, Vaccines and Therapeutics by ruth on April 29, 2006
FDA Approves Genezyme's Myozyme
Almost a year after its application, the Food and Drug Administration granted Genzyme marketing approval for Myozyme® (alglucosidase alfa) in the United States. Myozyme has been approved for the treatment of patients with Pompe disease, a debilitating, progressive and often fatal muscle disorder This genetic disease is caused by a Deficiency in the enzyme acid alpha-glucosidase (GAA), leading to an accumulation of glycogen, subsequently causing progressive muscle weakness throughout the body, particularly in the heart, skeletal muscles, liver, and nervous system.
Myozyme has received orphan drug designation in the United States, which provides seven years of market exclusivity. The orphan drug law is designed to encourage the development of treatments for rare disorders such as Pompe disease, for which no therapies have existed previously. Genzyme expects to launch Myozyme in the United States within two weeks.

The product, also approved in the EU, is the first treatment ever approved for Pompe disease and the first for a genetic neuromuscular disorder.

[Source: Genzyme]


Permalink: FDA Approves Genezyme's Myozyme
Tags: muscle  enzyme  biotech  myozyme  genezyme  genezyme+myozyme  approves+genezyme  pompe+disease 
Trackback: http://publish.creative-weblogging.com/publish/mt-tb.pl/21029
img Addthis img Ask img Blinklist img del.icio.us img Digg img Fark img Facebook img Google img Lycos img Ma.gnolia Add this page to Mister Wong Mr Wong img Netscape img Netvousz img Newsvine img Reddit img StumbleUpon img Slashdot img Tailrank img Technorati img Wink img Yahoo

Vote for FDA Approves Genezyme's Myozyme:

  • Currently 6.00/10
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
Rating: 6.00 out of 1 vote(s) cast.
 
Subscribe
Share It
Popular posts from our other blogs:
RSSrss
See all blog subscribe options
Google google
What is RSS?
Yahoo! yahoo
Addthis Subscribe using any feed reader!
Bloglines Bloglines
Newsletter

TwitterFollow us on Twitter!